The FRONTIER Study will determine the effectiveness of an emergency drug called NA-1 in reducing brain damage and disabilities in patients experiencing an acute stroke.
Currently, paramedics use a provincial stroke protocol, in close collaboration with on-line medical support, to identify eligible patients and transport them to a stroke care centre.
All stroke patients will continue to receive the current standard of care. Patients enrolled in the FRONTIER study will also receive NA-1 (or placebo) and be carefully followed for 90 days. The study, if positive, will change the management of stroke by paramedics.
The study involves paramedics who transport patients with a suspected stroke to The Royal Columbian Hospital, Kelowna General Hospital and Vancouver General Hospital. It is supported by a Multi-Investigator Research grant from the Brain Canada Foundation and sponsored by NoNO Inc., the Canadian company who developed NA-1.
On 4th September 2018, the 279th FRONTIER patient was enrolled in Kelowna, marking 50% enrollment. We are currently reaching our enrollment target, with an average of ten patients per month enrolled in the study.
Thank you to all of our FRONTIER paramedics for your hard work and persistence in reaching this important milestone. We look forward to continued success and ultimately the results of the trial.